Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sekisui Chemical To Acquire U.S. CRO XenoTech

This article was originally published in PharmAsia News

Executive Summary

TOKYO - In an effort to expand its U.S. presence in preclinical services, Sekisui Chemical Co. says it plans to acquire Kansas-based contract research organization XenoTech in an undisclosed, all-cash transaction by the end of July

You may also be interested in...



A Divesture To Kick Up Valuation For Genzyme Drives U.S. Expansion For Japanese Diagnostic Firm

TOKYO - True to its word, Genzyme sold off its diagnostics business, the second of three units the company said it would divest to generate shareholder value, but which is seen largely as a move to enhance valuation as it courts buyers. The Genzyme unit was sold to Japanese firm Sekisui Chemical, a young company that has been quick to expand its presence in the U.S

A Divesture To Kick Up Valuation For Genzyme Drives U.S. Expansion For Japanese Diagnostic Firm

TOKYO - True to its word, Genzyme sold off its diagnostics business, the second of three units the company said it would divest to generate shareholder value, but which is seen largely as a move to enhance valuation as it courts buyers. The Genzyme unit was sold to Japanese firm Sekisui Chemical, a young company that has been quick to expand its presence in the U.S

A Divesture To Kick Up Valuation For Genzyme Drives U.S. Expansion For Japanese Diagnostic Firm

Sale is the second of three units Genzyme said it would divest to generate shareholder value, but which is seen largely as a move to enhance valuation as it courts buyers.

UsernamePublicRestriction

Register

OM016193

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel